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Title: Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of 
Decompensation 
 
Abstract:  
Background & Aims: It is important to rapidly identify patients with advanced liver disease. Routine 
tests to assess liver function and fibrosis provide data that can be used to determine patients’ 
prognoses. We tested the validated the ability of combined data from the ALBI and FIB-4 scoring 
systems to identify patients with compensated cirrhosis at highest risk for decompensation. 
Methods: We collected data from 145 patients with compensated cirrhosis (91% Child A cirrhosis 
and median MELD scores below 8) from a cohort in Nottingham, United Kingdom, followed for a 
median 4.59 years (development cohort). We collected baseline clinical features and recorded 
decompensation events. We used these data to develop a model based on liver function (assessed by 
the ALBI score) and extent of fibrosis (assessed by the FIB-4 index) to determine risk of 
decompensation. We validated the model in 2 independent external cohorts (1 in Dublin, Ireland and 
1 in Menoufia, Egypt) comprising 234 patients. 
 
Results: In the development cohort, 19.3% of the patients developed decompensated cirrhosis. Using 
a combination of ALBI and FIB-4 scores, we developed a model that identified patients at low vs high 
risk of decompensation (hazard ratio [HR] for decompensation in patients with high risk score was 
7.10). When we tested the scoring system in the validation cohorts, the HR for decompensation in 
patients with a high-risk score was 12.54 in the Ireland cohort and 5.10 in the Egypt cohort. 
 
Conclusion: We developed scoring system, based on a combination of ALBI and FIB-4 scores, that 
identifies patients at risk for liver decompensation. We validated the scoring system in 2 independent 
international cohorts (Europe and the Middle East), so it appears to apply to diverse populations. 
 
 
KEY WORDS: liver failure, prognostic factor, alcohol-associated liver disease outcome, NAFLD 
prediction 
 
What You Need to Know  
Background: We combined data from the ALBI and FIB-4 scoring systems to develop a system to 
identify patients with compensated cirrhosis at highest risk for decompensation. 
 
Findings: Using a combination of ALBI and FIB-4 scores, we developed and validated a model that 
identified patients at low vs high risk of decompensation. 
 
Implications for patient care: We validated the scoring system in 2 independent international cohorts 
(Europe and the Middle East), so it might be used worldwide in determining the prognoses of patients 
with cirrhosis. 
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INTRODUCTION  
The progression of chronic liver disease (CLD), from fibrosis to clinical outcomes, and clinical sequelae 
including liver decompensation (ascites, variceal bleeding and encephalopathy) manifest relatively late in 
the natural history and are often the index presentation of liver disease (1). Identification of patients that 
need intensive monitoring and timely intervention is challenging. Robust prognostic tools using simple 
laboratory variables, with potential for implementation in non-specialist settings and across different health 
care systems, have significant appeal.  
 
The Child Pugh and MELD score are extensively validated and easily applicable tools that have been used for 
decades in clinical practice; the caveats that limit their performance have been previously documented  (2-
4). Importantly, these scoring systems provide value after synthetic liver function has become significantly 
deranged and provide only short term prognostic value.  Presently, there are no scores, performed in routine 
clinical practice, that provide robust prognostic stratification within early, compensated cirrhosis over the 
medium/long term. 
 
Serum albumin and bilirubin have recently been combined in a statistical model as the ‘ALBI score’, a 
measure of liver function in patients with HCC (5-8).  This model has been extensively validated and 
subsequently extended to patients with chronic liver disease (without HCC) in a variety of clinical settings (9-
11). We hypothesised that the ALBI score, being a measure of hepatic reserve, would be related to the risk 
of subsequent liver decompensation and tested this hypothesis in the setting of a prospective, longitudinal 
cohort of patients with compensated cirrhosis in Nottingham, UK. We further explored the combination ALBI 
with of markers of liver fibrosis (tracking progression of liver disease) as measured by the Fib-4 index. (12-
14).  Finally, we sought to validate this combined assessment of fibrosis and function in two independent, 
external cohorts.   
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PATIENTS AND METHODS 
Our primary analysis and model building was focussed on the prospective, longitudinal Nottingham (UK) 
cohort. We then tested the generalisability of our findings on two independent cohorts from Dublin (Ireland) 
and Menoufia (Egypt).  
 
 Prospective Nottingham (UK) cohort  
Patients were consecutively recruited from the Nottingham compensated cirrhosis cohort study (3CN). The 
3CN study is a prospective, longitudinal study initiated in 2010 focussed on the study of early compensated 
liver cirrhosis. The study was approved by a NHS ethics committee and standard regulatory requirements 
obtained (10/H0403/10). Inclusion criteria were patients between the ages of 18-75 years, an established 
diagnosis of cirrhosis obtained by at least one of the following criteria: histology, radiological or endoscopic 
evidence of portal hypertension, clinical evidence of cirrhosis with thrombocytopenia and validated non-
invasive liver fibrosis test (Transient elastography >15 kPa).  Exclusion criteria included the presence of 
hepatocellular carcinoma at baseline, portal or splenic vein thrombosis, clinical or radiological ascites at 
baseline visit, history of variceal haemorrhage and any previous episode of clinical encephalopathy. Patients 
at baseline had blood tests drawn for routine laboratory measures which included albumin, bilirubin and 
platelet count. Patients were followed up at six monthly visit appointments until the end of the study 
duration (10/08/2016). At each clinic visit, routine bloods were drawn for assessment of liver function, full 
blood count, clotting and renal function and assessment made for the appearance of a liver related clinical 
event in the intervening period. At the end of the study all patients were assessed for clinical outcomes using 
digital hospital records and contacting primary care physicians directly in those failing to attend secondary 
care.  
 
Validation cohorts  
Prospective Dublin (Ireland) cohort 
Patients were screened at general hepatology outpatients for inclusion criteria and following consent, were 
invited for a study visit.  Enrolment was consecutive and occurred between August 2011 and April 2015.  
Cirrhosis at this site was confirmed by one of the following criteria:  histology proving cirrhosis, endoscopic 
or radiological evidence of varices and thrombocytopenia (platelets <150x109) or radiological evidence of 
splenomegaly (spleen >11cm) or LSM >12 kPa.  Patients were excluded if they had any of the following: 
diagnosis of hepatocellular carcinoma, splenic or portal vein thrombosis, brain injury or unconsciousness, 
dementia, active substance use that would preclude clinic visits, and decompensated liver disease (clinical 
or radiological ascites at baseline visit, history of variceal bleeding and overt clinical encephalopathy). The 
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date and nature of hepatic decompensation, occurring after enrolment in the study, were collected by a liver 
specialist and supported with either endoscopy reports, abdominal imaging or hospitalization report.  
 
Retrospective Menoufia (Egypt) cohort  
Patients were recruited from the outpatient clinic at the National Liver Institute, Menoufia University, Egypt. 
This was a retrospective cohort starting in 2006 and only patients with complete follow up data were 
included. Patients diagnosed with liver cirrhosis were included after fulfilling at least one of the following 
criteria: histopathological diagnosis by liver biopsy, radiological or endoscopic evidence of portal 
hypertension or transient elastography >14 kPa.  Patients with missing data, hepatocellular carcinoma at 
baseline, history of any malignancies, evidence of portal or splenic vein thrombosis and any patient with 
history of hepatic decompensation at time of diagnosis (clinical or radiological ascites, variceal bleeding and 
any previous episode of clinical encephalopathy) were excluded from the study. Routine laboratory 
diagnostic tests were performed including serum albumin, bilirubin and platelet count. Hepatic 
decompensation, following enrolment in the study, were ascertained by clinicians in charge of their care and 
supported with either endoscopy reports, abdominal imaging or hospitalization report.  
 
Statistical methods 
Stata/SE 14.2 (StataCorp, Texas, USA) and R software (R 3.4.4)(15) were used to undertake the analysis. 
Continuous variables were presented as median (with interquartile range) and categorical variables were 
presented as percentages. Highly skewed variables were log10 transformed.  The primary outcome was 
hepatic decompensation. This was defined using the clinical parameters of first episode of ascites (as defined 
by confirmation with ultrasonography and  requiring treatment with diuretics or paracentesis)  or the first 
variceal bleed  (defined by requiring endoscopic intervention)  or the  first episode of encephalopathy , 
assessed by an experienced  clinician and defined by Grade 3 / 4 West Haven classification ; whichever event 
occurred first. Time to decompensation (TTD) was calculated from date of entry to study until date of first 
recorded decompensation. Patients were censored if they underwent liver transplantation or died. Deaths, 
occurring in hospital and outside the hospital, were collected by using a combination of hospital patient 
records (Nottingham, Dublin and Egypt), family practitioner records (Nottingham and Dublin), death 
certificates (Nottingham, Dublin and Egypt) and telephone interviews with relatives (Egypt).  When the  
prospective study in Nottingham was initiated we planned for 50 % decompensation rate at 4 years based 
on a systematic review by D'Amico and colleagues (16). Therefore, we estimated a cohort of n=150, followed 
for at least 4 years, would yield 75 events. Using the 10:1 rule of thumb for prediction models, we anticipated 
this would allow us to explore at least 7 prognostic variables. We did not use imputation for missing variables. 
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ALBI vs MELD 
Liver function was initially measured by ALBI or MELD score. Univariable Cox regression was undertaken for 
both variables. Decompensation risk predictions by MELD and ALBI were compared using Harrell’s C statistic 
(17), Gönen & Heller’s K (18) and Royston & Sauerbrei’s R2D (19). Higher values of these measures translate 
to better survival prediction. Confidence intervals (C.I.) and p-values of the comparisons were estimated 
using the bootstrap method (1000 samples).  Patients who have both ALBI and MELD recorded where 
included in this part of the analysis. 
 
Association between ALBI, FIB-4 and TTD 
TTD according to baseline ALBI grade were examined via Kaplan-Meier (KM) graphs and compared using the 
log-rank test. Association between ALBI score and FIB-4 (appendix 1) and TTD was tested using univariable 
Cox regression analysis.  
 
Building of the ALBI-FIB4 Score 
 A multivariable Cox model combining ALBI score and FIB-4 was generated. Model fit was compared to the 
univariable models using the log-likelihood ratio (LR) test.  Any violation in the proportional hazards 
assumption was tested by examining the Schoenfeld residuals. The formula for the new score (linear 
predictor) was produced using the coefficients of the model. A high risk group of patients were identified by 
applying a cut-off at the 85th centile of the score (patients within the top 15% risk). Our usual approach has 
been to define four classes based on cut-offs at the 15th, 50th and 85th centile of the linear predictor as 
proposed by Cox and Royston (20, 21). However in this study, the numbers of decompensation events was 
too small to justify a four class model and we therefore used the 85th centile figure as the cut-off.  
 
Model performance and validation 
The new model was validated in two independent external cohorts from Dublin (Ireland) and Menoufia 
(Egypt). Median survival, hazard ratios and percentage decompensation at 3 and 5 years were calculated for 
each risk group in both the derivation and validation sets. KM graphs according to the two risk groups were 
also plotted for the derivation and validation sets. 
In order to make the formula applicable to a clinics setting we developed a simple online calculator 
(https://jscalc.io/calc/gdEJj89Wz5PirkSL). 
 
Model comparisons 
The discriminatory performance of ALBI-FIB4 score was compared to the other scores, namely ALBI, FIB-4, 
MELD, and Child-Pugh score using Harrell’s C statistic, Gönen & Heller’s K and Royston & Sauerbrei’s R2D. 
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Models were also compared using integrated discrimination improvement (IDI) and category-free net 
reclassification improvement (NRI>0).  IDI measures the difference in the discrimination slopes between the 
new model ALBI-FIB4 and the older models (ALBI, FIB4, MELD and Child-Pugh).(22) Discrimination slope is a 
measure of the separation in predicted probabilities for events and non-events.(23) NRI measures the 
amount of correct reclassifications by the new model (ALBI-FIB4) compared to the older models (ALBI, FIB4, 
MELD and Child-Pugh) based on calculated predicted risk probabilities.(22-24). In this analysis, an extension 
of IDI and NRI that incorporates censored survival data was used.(24, 25)  Confidence intervals (C.I.) and p-
values for IDI and NRI were estimated using perturbation-resampling (1000 iterations). Model comparisons 
was undertaken in both the derivation and validation sets. Due to the low number of decompensation events 
and in order to improve the statistical power, both validation sets were combined.  
 
 
 
 
RESULTS  
The Nottingham cohort comprised 145 patients with cirrhosis (91% Child Pugh A grade).  The most common 
aetiology was alcohol (44.8%) followed by non-alcoholic fatty liver disease (29.7%) and other aetiologies as 
shown in Table 1. The median length of follow-up was 4.59 years (95% CI 4.02, 4.90), with an overall 
decompensation rate of 19.3% and an overall survival of 82.1%. The most common decompensation event 
was ascites development (71.4 %) followed by variceal bleeding (21.4 %) and grade 3/4 encephalopathy (7.2 
%). The median ALBI score at baseline was -2.43 ( -2.72 to -2.18).  
 
The Dublin cohort comprised of 141 patients with cirrhosis (90% Child Pugh Grade A).  The most common 
aetiology was alcohol (39.7%) followed by HCV (29.8%). The overall decompensation rate was 12.1% over a 
maximum time of 6.4 years. The most common decompensation event was variceal haemorrhage (47.1%), 
followed by ascites (29.4%) and encephalopathy (both 23.5%). The median ALBI score at baseline was -2.48 
(-2.71 to -2.13).  
 
The Menoufia cohort comprised of 93 patients with cirrhosis (88% Child Pugh Grade A). The most common 
aetiology was NAFLD (47.3%) followed by HCV (34.4%). The overall decompensation rate was 38.7 % over a 
maximum time of 10.6 years. The most common decompensation event was ascites (57.1%), followed by 
variceal bleeding (22.9%), followed by encephalopathy (14.3%). The median ALBI score at baseline was -2.52 
(-2.93 to -2.05) 
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ALBI vs MELD 
Both baseline ALBI score and MELD were significantly influenced decompensation with hazard ratios (HR) 
7.90 (95% C.I. 3.37, 18.54), p<0.0001 and 1.20 (95% C.I. 1.07, 1.35), p=0.002 respectively. The Harrell’s C 
statistic, Gönen & Heller’s K and Royston & Sauerbrei’s R2D for ALBI vs MELD were as follows: 0.755 (95% 
C.I. 0.663, 0.835) vs 0.715 (95% C.I. 0.621, 0.804), 0.699 (95% C.I. 0.634, 0.747) vs 0.583 (95% C.I. 0.531, 
0.651) and 0.374 (95% C.I. 0.164, 0.560) vs 0.213 (95% C.I. 0.058, 0.411) respectively. In all three measures, 
ALBI showed higher values compared to MELD, although some of these were not significant (p=0.480, 
p=0.001 and p=0.122 respectively).   Furthermore, adding MELD to FIB-4 did not improve the fit of the model 
(LR test, p=0.4058) compared to adding ALBI score to FIB-4 (p=0.0078).  ALBI was therefore considered a 
better measure for liver function compared to MELD for the purpose of this analysis. 
 
Association between ALBI, FIB-4 and TTD 
As expected in a cohort of compensated cirrhosis, the majority of patients were in ALBI grade 1 (34.5%) or 
ALBI grade 2 (63%) with only a minority in grade 3 (3%).  Figure 1 shows TTD according to baseline ALBI grade 
1 and 2. There were significant (p=0.0102) differences in TTD curves between the two grades.  Univariable 
Cox regression analysis showed that both ALBI score (HR 6.09 [95% C.I. 2.87, 12.96], p<0.0001) and FIB-4 (HR 
1.26 [95% C.I. 1.14, 1.40], p<0.0001) strongly influenced TTD.  
 
Building of the ALBI-FIB4 Score 
A multivariable Cox regression model that combined ALBI and FIB-4 scores had a better fit compared to when 
either of the variables were taken alone (likelihood ratio test p=0.0167, upon adding FIB-4 to ALBI score and 
p=0.0069 vice versa).  In the multivariable model, the hazard ratio, 95% C.I. and p-value for the ALBI score 
and FIB-4 were 3.79 (1.53, 9.36), p=0.004 and 1.18 (1.05, 1.33), p=0.008 respectively. 
 
The formula for this new ALBI-FIB4 score was as follows: (ALBI score*1.331) + (FIB-4*0.165). Patients with a 
score greater than -1.822 were considered high risk whereas those equal to or below -1.822 as low risk.  
 
Model performance and validation  
Nottingham, UK (derivation cohort)  
Using the ALBI-FIB4 score, 85% of the cohort were stratified in the low risk group and 15% stratified in the 
high risk group. The groups showed clear separation (p<0.0001) in those reaching a clinical end point of 
decompensation (Figure 2A). In the low risk group at baseline, 9.3 % reached a decompensation event within 
3 years. This is in contrast to those in a high risk group where 48.4 % reached a decompensation event rate 
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within 3 years (Table 2). The hazard ratios of reaching a decompensation event was 7.10 (95% C.I. 3.07 to 
16.42) in the high risk group compared to the low risk group.  
 
Dublin, Ireland and Menoufia, Egypt (external validation cohorts)   
In the external validation cohorts the ALBI-FIB4 index stratified 81% of the Egyptian cohort and 82% of the 
Irish cohort into the low risk group. The high and low risk groups again showed clear separation (p<0.001) in 
both validation cohorts (Figure 2B and 2C). The hazard ratio of reaching decompensation between the low 
and high risk groups was 12.54 (95% C.I. 4.25 to 36.93) in the Irish cohort and 5.10 (95% C.I. 2.07 to 12.59) 
in the Egyptian cohort. Percentage of patients reaching decompensation event within the first 3 or 5 years 
in the two validation cohorts are shown in Table 2. 
 
Model comparisons 
Table 3 displays survival prediction comparisons between ALBI-FIB4 and other scores, namely ALBI, FIB-4, 
MELD and Child-Pugh score using Harrell’s C statistic, Gönen & Heller’s K,Royston & Sauerbrei’s R2D, IDI and 
NRI in both the derivation and validation sets. The table shows that overall ALBI-FIB4 and in some instances, 
ALBI score, gave higher values of the five measures compared to the rest, although there may not be enough 
statistical power to detect significant differences in many of the comparisons due to low number of 
decompensation events.  
 
 
DISCUSSION  
We have validated the ALBI score in a prospectively accrued data set as a measure of liver dysfunction in 
patients with chronic liver disease. In addition, we created a new score, ‘ALBI-FIB4’ which can effectively 
stratify patients for the risk of future liver decompensation. The ALBI-FIB4 score identified a high risk group 
more effectively than the MELD score and maintained performance in two external cohorts with distinct 
differences in aetiology of cirrhosis.  
 
The Nottingham cohort represents early compensated cirrhosis as evidenced by the fact that 91% of the 
cohorts were Child Pugh stage A (9% child Pugh stage B) with a median MELD score of less than 8 at baseline. 
This explains why the cohort had predominance of ALBI grade 1 (35%) or ALBI grade 2 (63%) at baseline; with 
only a small fraction of ALBI grade 3 (3%).  When followed prospectively over 5 years the ALBI grade showed 
impressive prognostic separation; a decompensation rate of 11.5 % versus 27.3 % in grade 1 versus grade 2 
respectively.  The validation of ALBI in a compensated cirrhosis cohort of mixed aetiology supports previous 
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findings in  compensated cirrhosis and chronic hepatitis B (11). Prior to this, the body of evidence for ALBI 
was focussed on patients with hepatocellular carcinoma (5-8).  
 
FIB-4 has been extensively validated as a non-invasive marker of fibrosis and shown to have a prognostic 
ability to predict clinical outcomes across chronic liver disease including HCV, HBV and NAFLD (12-14). The 
ALBI score is postulated to show early changes in synthetic function and the use of the ratio results in more 
sensitivity than simply observing for the individual parameters to cross the upper limit of normal.  The 
combination has biological plausibility, by looking at markers of fibrosis and function simultaneously. The 
combined score showed superiority within the multivariable cox regression model but this was not 
translated to statistical differences in Harrell’s C statistic or IDI/NRI.  
 
An important strength of our study is that we utilised the robust clinical end points of ascites, 
encephalopathy and variceal bleeding as originally described in the seminal natural history studies of 
cirrhosis (26, 27). We did not use jaundice or change in Child Pugh classification as these are directly 
influenced by prognostic variables we chose to study. The Nottingham cohort is a mixed aetiology cohort 
with compensated cirrhosis followed prospectively for clinical events. This cohort represents a formal, 
prospective, protocol driven study designed a priori to document the clinical history of patients with 
compensated cirrhosis.  The collection of hard clinical outcomes, using a variety of source documents, was a 
central aspect of this study but we accept that within each cohort intrinsic limitations exist; e.g. a patient 
migrating to another health region during the period of study.  The prevalence of the different aetiologies, 
with alcohol the dominant aetiology followed by NAFLD and viral hepatitis is very similar to a large 
population study of UK patients with cirrhosis (28). This implies the data has direct application to a 
population in which simple markers such as ALBI and FIB-4 has the greatest relevance. The validation cohort 
from Ireland, driven by the aetiologies of alcohol and HCV was in contrast to the cohort from Egypt with the 
predominant aetiologies of HCV and NAFLD. This provides reassurance that the model has generalisability 
for stratifying liver disease at an international level.  A limitation of stratification based on the ALB-FIB-4 
score is that only 15% are classified in the high risk group).  We deliberately focussed on the previously 
validated scores of ALBI and FIB-4 in this study as our aim was to create a tool that could be used within a 
community setting or low resource countries.  
 
A frequently levelled criticism of algorithms such as ALBI-FIB-4 is that they are too complicated to be applied 
routinely in the clinical setting. To overcome this problem we developed  a simple online calculator which 
can be  accessed using the following link: https://jscalc.io/calc/gdEJj89Wz5PirkSL.With respect to 
comparable models which are routinely performed in clinical practice, the ALBI-FIB-4 score was numerically 
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superior to the other scores including the MELD score and Child Pugh Score. However a limitation of the low 
number of events was that we were not able to show consistent statistical superiority or look at a wide 
number of variables in the analysis.  
 
We have shown that routinely available laboratory variables, combined in a novel algorithm ALBI-FIB-4, can 
stratify patients with cirrhosis for future risk of liver decompensation. The ability to do this in the context 
of early, compensated cirrhosis with preserved liver synthetic function whilst also predicting long term 
clinical outcomes has clinical utility for international health care systems.   
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Appendix 1  
 
ALBI-score:  
(log10 bilirubin[μmol/l] x 0.66) + (albumin[g/l] x - 0.085) 
FIB-4 score : Age × AST (IU/L)/ platelet count (×109/L) × √ALT (IU/L)  
 
Legends for tables and figures  
 
Table 1: Baseline characteristics of cohorts 
 
Table 2: Summary of median decompensation, percentage decompensation at 3 and 5 years with hazard 
ratios of the different categories 
 
Table 3: Comparing ALBI-FIB4 model to other scores 
 
Figure 1: Decompensation using ALBI grade at baseline in Nottingham cohort  
 
Figure 2: Time to decompensation according to the (A) UK (B) Ireland and  (C) Egypt cohorts using 
combined ALBI-FIB-4 score 
 
